secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001683168-21-005361
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma signs 20-year exclusive license & distribution deal with Dyamed for four Southeast Asian markets
--------------------------------------------------------------------------------

- Exclusive rights for hypochlorous acid products (dermatology, eye, oral) in Singapore, Malaysia, Indonesia, and Thailand.
- 20-year term; Dyamed pays royalty and transfer prices (amounts redacted).
- Minimum annual purchase commitments in USD for first 10 years (redacted).
- Exclusive license to use Sonoma's Microcyn trademark in the Territory.
- Dyamed responsible for regulatory approvals, marketing, and distribution at its own cost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316821005361/0001683168-21-005361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316821005361/snoa_i8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-005361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer